What is the dosing range for IGF-1 DES?

IGF-1 DES is typically dosed at 50mcg (low), 100mcg (moderate), or 150mcg (high) mcg, administered 1–2x daily, preferably post-workout. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of IGF-1 DES?

Reported side effects of IGF-1 DES include: Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses, Potential promotion of pre-existing tumors (IGF-1R is overexpressed in many cancers), Transient fatigue.

Performance

IGF-1 DES

Also known as: Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1

IGF-1 DES is a research compound not approved for human use. For informational purposes only.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.

Research Summary

The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.

Dosing Range

low

50mcg

moderate

100mcg

high

150mcg

Units: mcg · Frequency: 1–2x daily, preferably post-workout

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injectionIntramuscular injection (into target muscle for local hypertrophic effect)

Reconstitution Notes

Reconstitute with bacteriostatic water to 1mg/mL. Short half-life (~20–30 min) — inject within 30 minutes of reconstitution from the vial for maximum activity. Store as lyophilized powder until ready to use. Stable 28 days refrigerated after reconstitution if needed.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby)
Localized muscle swelling at injection site
Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent)
Organ enlargement at excessive doses
Potential promotion of pre-existing tumors (IGF-1R is overexpressed in many cancers)
Transient fatigue

Research Papers

2 peer-reviewed sources

Des(1-3)IGF-I is a more potent stimulus to muscle protein synthesis than normal IGF-I

American Journal of Physiology1992

Truncated IGF-1 variant and IGFBP interactions — mechanism of enhanced potency

Endocrinology1993

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Peptides

Community protocols comparing IGF-1 LR3 vs DES — localized vs systemic effects, PWO injection timing.

View original thread

r/bodybuilding

Bodybuilding community experience with IGF-1 DES for targeted muscle growth protocols.

View original thread

Overview

IGF-1 comes in many forms. The standard long-acting research variant (IGF-1 LR3) is designed to resist IGFBP binding through an Arg3 substitution. IGF-1 DES takes a different approach — it is a naturally occurring truncated version found in highest concentrations in the brain, gut, and at sites of active muscle regeneration, and it avoids IGFBP binding simply by lacking the binding domain entirely.

IGF-1 DES vs IGF-1 LR3

| Property | IGF-1 LR3 | IGF-1 DES | |----------|-----------|-----------| | Mechanism | Arg3 substitution resists IGFBP binding | N-terminal truncation eliminates IGFBP binding site | | Half-life | 20–30 hours | 20–30 minutes | | Potency vs native IGF-1 | ~3x | ~10x | | Distribution | Systemic (long-acting) | Primarily local (short-acting) | | Best use | Systemic IGF-1 elevation, daily dosing | Targeted post-workout injection into worked muscle | | Hypoglycemia risk | Moderate | Higher (more rapid effect) |

LR3 is better for overall IGF-1 tone; DES is better for post-workout local muscle stimulation.

Local Muscle Hypertrophy

Because of its short half-life, IGF-1 DES acts primarily at the site of injection. Intramuscular injection into a worked muscle post-training concentrates its effect there:

Activates satellite cells (muscle stem cells) in the injected muscle
Stimulates local mTOR pathway → protein synthesis
Promotes myoblast differentiation into new muscle fibers (hyperplasia vs hypertrophy)

Hypoglycemia Risk

IGF-1 DES is significantly more potent than standard IGF-1. Its rapid, intense receptor activation can drive glucose into cells quickly, causing hypoglycemia — particularly if injected without food. Always have fast-acting carbohydrates available. Post-workout injection with a post-training meal is the standard protocol to minimize this risk.

Combination Protocols

Commonly combined with:

Mod-GRF(1-29) + Ipamorelin (pre-sleep): GH pulse → hepatic IGF-1 production. DES IGF-1 injected post-workout acts locally while GH peptides support systemic IGF-1 levels
Testosterone/AAS cycles: IGF-1 DES added for hypertrophic synergy — androgen receptors and IGF-1 receptors signal independently through convergent pathways